In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Melissa Lattanzi, VP, Emerging Therapies, Cencora ...

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued ...

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing ...

The National Institute for Public Employee Healthcare Policy attributed the importance to the rising cost of health care.

Respondents said they were concerned about their own mental health or the mental health of another person at higher rates ...

It’s long past time for the industry to fully embrace the digital age. It’s fine to keep paper back-ups of data, but using ...

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare ...

The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina ...

The FDA first approved Ozempic, Novo Nordisk’s GLP-1 receptor agonist to improve glycemic control in adults with type 2 ...

Myhibbin is reportedly the first FDA-approved liquid formulation of mycophenolate, a key immunosuppressant used to prevent ...

Acceptance of the application was based on promising results from the Phase III CheckMate -67T study, which displayed ...

For decades, one of the main priorities of the United States healthcare system has been to develop life-saving treatments for ...